Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Luuk Wieske; Eileen W. Stalman; P. J. Koos van Dam; Laura Y. Kummer; Maurice Steenhuis; Zoe L. E. van Kempen; Joep Killestein; Adriaan G. Volkers; Sander W. Tas; Laura Boekel; Gertjan Wolbink; Anneke van der Kooi; Joost Raaphorst; Mark Löwenberg; Bart Takkenberg; Geert R. A. M. D'Haens; Phyllis I. Spuls; Marcel W. Bekkenk; Annelie H. Musters; Nicoline F. Post; Angela L. Bosma; Marc L. Hilhorst; Yosta Vegting; Frederique J. Bemelman; Alexandre Voskuyl; Bo Broens; Agner Parra Sanchez; C. cile A. C. M. van Els; Jelle De Wit; Abraham Rutgers; Karina de Leeuw; Barbara Horváth; Jan J. G. M. Verschuuren; Annabel M. Ruiter; Lotte van Ouwerkerk; Diane van der Woude; Cornelia F. Allaart; Y. K. Onno Teng; Pieter van Paassen; Matthias H. Busch; Papay B. P. Jallah; Esther Brusse; Pieter A. van Doorn; Adája Elisabeth Baars; Dirkjan Hijnen; Corine R. G. Schreurs; W. Ludo van der Pol; H. Stephan Goedee; Sofie Keijzer; Jim Keijser; Olvi Cristianawati; Anja ten Brinke; Niels J. M. Verstegen; Koos A. H. Zwinderman; S. Marieke van Ham; Taco W. Kuijpers; Theo Rispens; Filip Eftimov

doi:https://doi.org/10.1136/ard-2022-223464

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Luuk Wieske, Eileen W. Stalman, P. J. Koos van Dam, Laura Y. Kummer, Maurice Steenhuis, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gertjan Wolbink, Anneke van der Kooi, Joost Raaphorst, Mark Löwenberg, Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. PostAngela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederique J. Bemelman, Alexandre Voskuyl, Bo Broens, Agner Parra Sanchez, C. cile A. C. M. van Els, Jelle De Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adája Elisabeth Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Sofie Keijzer, Jim Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Filip Eftimov

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used.1 It is largely unknown how antibody titres develop over time and whether it is needed to adjust timing of booster campaigns for patients with IMID.

Original language	English
Article number	ard-2022-223464
Pages (from-to)	883-885
Number of pages	3
Journal	Annals of the rheumatic diseases
Volume	82
Issue number	6
Early online date	2023
DOIs	https://doi.org/10.1136/ard-2022-223464
Publication status	Published - 1 Jun 2023

Keywords

Autoimmune Diseases
Covid-19
Tumor Necrosis Factor Inhibitors
Vaccination

Access to Document

https://doi.org/10.1136/ard-2022-223464

Cite this

Wieske, L., Stalman, E. W., van Dam, P. J. K., Kummer, L. Y., Steenhuis, M., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G., van der Kooi, A., Raaphorst, J., Löwenberg, M., Takkenberg, B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., ... Eftimov, F. (2023). Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases. Annals of the rheumatic diseases, 82(6), 883-885. Article ard-2022-223464. https://doi.org/10.1136/ard-2022-223464

@article{e911a2c361c044aebf212bf3f215c0ec,

title = "Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases",

abstract = "Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used.1 It is largely unknown how antibody titres develop over time and whether it is needed to adjust timing of booster campaigns for patients with IMID.",

keywords = "Autoimmune Diseases, Covid-19, Tumor Necrosis Factor Inhibitors, Vaccination",

author = "Luuk Wieske and Stalman, {Eileen W.} and {van Dam}, {P. J. Koos} and Kummer, {Laura Y.} and Maurice Steenhuis and {van Kempen}, {Zoe L. E.} and Joep Killestein and Volkers, {Adriaan G.} and Tas, {Sander W.} and Laura Boekel and Gertjan Wolbink and {van der Kooi}, Anneke and Joost Raaphorst and Mark L{\"o}wenberg and Bart Takkenberg and D'Haens, {Geert R. A. M.} and Spuls, {Phyllis I.} and Bekkenk, {Marcel W.} and Musters, {Annelie H.} and Post, {Nicoline F.} and Bosma, {Angela L.} and Hilhorst, {Marc L.} and Yosta Vegting and Bemelman, {Frederique J.} and Alexandre Voskuyl and Bo Broens and {Parra Sanchez}, Agner and {van Els}, {C. cile A. C. M.} and Wit, {Jelle De} and Abraham Rutgers and {de Leeuw}, Karina and Barbara Horv{\'a}th and Verschuuren, {Jan J. G. M.} and Ruiter, {Annabel M.} and {van Ouwerkerk}, Lotte and {van der Woude}, Diane and Allaart, {Cornelia F.} and Teng, {Y. K. Onno} and {van Paassen}, Pieter and Busch, {Matthias H.} and Jallah, {Papay B. P.} and Esther Brusse and {van Doorn}, {Pieter A.} and Baars, {Ad{\'a}ja Elisabeth} and Dirkjan Hijnen and Schreurs, {Corine R. G.} and {van der Pol}, {W. Ludo} and Goedee, {H. Stephan} and Sofie Keijzer and Jim Keijser and Olvi Cristianawati and {ten Brinke}, Anja and Verstegen, {Niels J. M.} and Zwinderman, {Koos A. H.} and {van Ham}, {S. Marieke} and Kuijpers, {Taco W.} and Theo Rispens and Filip Eftimov",

note = "Funding Information: FE and TWK report (governmental) grants from ZonMw to studyimmune response after SARS-Cov-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSlBehring; and honoraria from Grifols. AJvdK reports grants from CSLBehring and participation on an advisory board for Argen-X. ML reports agrant from Galapagos not related to this study, and honoraria from BristolMyers Squibb, Pfizer, Takeda and Tillotts. PIS is involved in clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, for example, psoriasis and atopic dermatitis, for which financial compensation is paid to the department or hospital, and is achief investigator of the TREAT NL registry taskforce and SECURE-AD registry. MWB is a secretary for the Dutch Experimental Dermatology Board; head of the pigmentary disorders group within the Dutch Dermatology Board; and reports honoraria from Pfizer, Sanofi, Novartis, and Fondation Ren{\'e} Touraine. JK has speaking relationships with MerckSerono, Biogen Idec, TEVA, Sanofi, Genzyme, Roche and Novartis; received financial support to his institution for researchactivities from Merck Serono, Bayer Shcering Pharma, Biogen Idec, GlaxoSmithKline (GSK), Roche, Teva, Sanofi, Genzyme and Novartis. BH reports unpaid positions as a medical adviser for several patient groups, aboard position for ERN-SKIN, and associate editor for The British Journalof Dermatology; reports grants from AbbVIe, Akari Therapeutics, Celgene and Novartis; consulting fees from UCB Pharma, Novartis, and Janssen; and honoraria from AbbVie. JJGMV reports consulting fees from Argenx, Alexion and NMD Pharma, and is a coinventor on patent applicationsbased on MuSK-related research. DJH reportsgrants from AbbVie, AstraZeneca, Janssen, LEO Pharma and UCB; honoraria from AbbVie, Galderma, Janssen, Lilly, Pfizer, Sanofi, and UCB; and a paid position on an advisory board for BIOMAP IMI. PAvD participated on an advisory board for Octapharma. PvP reports grantsfrom Alexion Pharma and GSK, and participation on advisory boards for GSK and Vifor Pharma. GRAMD{\textquoteright}H reports consulting fees from AbbVie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, BristolMyers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, ExeliomBiosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity and Protagonist; honoraria from AbbVie, Arena, Galapagos, Gilead, Pfizer, Bristol MyersSquibb and Takeda; and participation on advisory boards for AbbVie, Seres Health, Galapagos, and AstraZeneca. RBT reports honoraria fromSobi and Norgine, and participation on an advisory board for Norgine. SHG is a board member of the Dutch Society of Clinical Neurophysiology (unpaid), reports grants from Prinses Beatrix Spierfonds, and receivedspeaker fees from Shire/Takeda. KAHZ reports paid data safetymonitoring board positions for Torrent and Foresee. Funding Information: This study was supported by ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007). Funding Information: We thank ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science), Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board.",

year = "2023",

month = jun,

day = "1",

doi = "https://doi.org/10.1136/ard-2022-223464",

language = "English",

volume = "82",

pages = "883--885",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "6",

}

Wieske, L , Stalman, EW, van Dam, PJK, Kummer, LY, Steenhuis, M, van Kempen, ZLE , Killestein, J, Volkers, AG, Tas, SW, Boekel, L, Wolbink, G , van der Kooi, A , Raaphorst, J , Löwenberg, M , Takkenberg, B , D'Haens, GRAM , Spuls, PI , Bekkenk, MW , Musters, AH , Post, NF, Bosma, AL, Hilhorst, ML , Vegting, Y, Bemelman, FJ, Voskuyl, A , Broens, B , Parra Sanchez, A, van Els, CCACM, Wit, JD, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, JJGM, Ruiter, AM, van Ouwerkerk, L, van der Woude, D, Allaart, CF, Teng, YKO, van Paassen, P, Busch, MH, Jallah, PBP, Brusse, E, van Doorn, PA, Baars, AE, Hijnen, D, Schreurs, CRG, van der Pol, WL, Goedee, HS, Keijzer, S, Keijser, J, Cristianawati, O, ten Brinke, A, Verstegen, NJM, Zwinderman, KAH , van Ham, SM , Kuijpers, TW , Rispens, T & Eftimov, F 2023, 'Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases', Annals of the rheumatic diseases, vol. 82, no. 6, ard-2022-223464, pp. 883-885. https://doi.org/10.1136/ard-2022-223464

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases. / Wieske, Luuk ; Stalman, Eileen W.; van Dam, P. J. Koos et al.
In: Annals of the rheumatic diseases, Vol. 82, No. 6, ard-2022-223464, 01.06.2023, p. 883-885.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

AU - Wieske, Luuk

AU - Stalman, Eileen W.

AU - van Dam, P. J. Koos

AU - Kummer, Laura Y.

AU - Steenhuis, Maurice

AU - van Kempen, Zoe L. E.

AU - Killestein, Joep

AU - Volkers, Adriaan G.

AU - Tas, Sander W.

AU - Boekel, Laura

AU - Wolbink, Gertjan

AU - van der Kooi, Anneke

AU - Raaphorst, Joost

AU - Löwenberg, Mark

AU - Takkenberg, Bart

AU - D'Haens, Geert R. A. M.

AU - Spuls, Phyllis I.

AU - Bekkenk, Marcel W.

AU - Musters, Annelie H.

AU - Post, Nicoline F.

AU - Bosma, Angela L.

AU - Hilhorst, Marc L.

AU - Vegting, Yosta

AU - Bemelman, Frederique J.

AU - Voskuyl, Alexandre

AU - Broens, Bo

AU - Parra Sanchez, Agner

AU - van Els, C. cile A. C. M.

AU - Wit, Jelle De

AU - Rutgers, Abraham

AU - de Leeuw, Karina

AU - Horváth, Barbara

AU - Verschuuren, Jan J. G. M.

AU - Ruiter, Annabel M.

AU - van Ouwerkerk, Lotte

AU - van der Woude, Diane

AU - Allaart, Cornelia F.

AU - Teng, Y. K. Onno

AU - van Paassen, Pieter

AU - Busch, Matthias H.

AU - Jallah, Papay B. P.

AU - Brusse, Esther

AU - van Doorn, Pieter A.

AU - Baars, Adája Elisabeth

AU - Hijnen, Dirkjan

AU - Schreurs, Corine R. G.

AU - van der Pol, W. Ludo

AU - Goedee, H. Stephan

AU - Keijzer, Sofie

AU - Keijser, Jim

AU - Cristianawati, Olvi

AU - ten Brinke, Anja

AU - Verstegen, Niels J. M.

AU - Zwinderman, Koos A. H.

AU - van Ham, S. Marieke

AU - Kuijpers, Taco W.

AU - Rispens, Theo

AU - Eftimov, Filip

N1 - Funding Information: FE and TWK report (governmental) grants from ZonMw to studyimmune response after SARS-Cov-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSlBehring; and honoraria from Grifols. AJvdK reports grants from CSLBehring and participation on an advisory board for Argen-X. ML reports agrant from Galapagos not related to this study, and honoraria from BristolMyers Squibb, Pfizer, Takeda and Tillotts. PIS is involved in clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, for example, psoriasis and atopic dermatitis, for which financial compensation is paid to the department or hospital, and is achief investigator of the TREAT NL registry taskforce and SECURE-AD registry. MWB is a secretary for the Dutch Experimental Dermatology Board; head of the pigmentary disorders group within the Dutch Dermatology Board; and reports honoraria from Pfizer, Sanofi, Novartis, and Fondation René Touraine. JK has speaking relationships with MerckSerono, Biogen Idec, TEVA, Sanofi, Genzyme, Roche and Novartis; received financial support to his institution for researchactivities from Merck Serono, Bayer Shcering Pharma, Biogen Idec, GlaxoSmithKline (GSK), Roche, Teva, Sanofi, Genzyme and Novartis. BH reports unpaid positions as a medical adviser for several patient groups, aboard position for ERN-SKIN, and associate editor for The British Journalof Dermatology; reports grants from AbbVIe, Akari Therapeutics, Celgene and Novartis; consulting fees from UCB Pharma, Novartis, and Janssen; and honoraria from AbbVie. JJGMV reports consulting fees from Argenx, Alexion and NMD Pharma, and is a coinventor on patent applicationsbased on MuSK-related research. DJH reportsgrants from AbbVie, AstraZeneca, Janssen, LEO Pharma and UCB; honoraria from AbbVie, Galderma, Janssen, Lilly, Pfizer, Sanofi, and UCB; and a paid position on an advisory board for BIOMAP IMI. PAvD participated on an advisory board for Octapharma. PvP reports grantsfrom Alexion Pharma and GSK, and participation on advisory boards for GSK and Vifor Pharma. GRAMD’H reports consulting fees from AbbVie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, BristolMyers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, ExeliomBiosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity and Protagonist; honoraria from AbbVie, Arena, Galapagos, Gilead, Pfizer, Bristol MyersSquibb and Takeda; and participation on advisory boards for AbbVie, Seres Health, Galapagos, and AstraZeneca. RBT reports honoraria fromSobi and Norgine, and participation on an advisory board for Norgine. SHG is a board member of the Dutch Society of Clinical Neurophysiology (unpaid), reports grants from Prinses Beatrix Spierfonds, and receivedspeaker fees from Shire/Takeda. KAHZ reports paid data safetymonitoring board positions for Torrent and Foresee. Funding Information: This study was supported by ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007). Funding Information: We thank ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science), Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used.1 It is largely unknown how antibody titres develop over time and whether it is needed to adjust timing of booster campaigns for patients with IMID.

AB - Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used.1 It is largely unknown how antibody titres develop over time and whether it is needed to adjust timing of booster campaigns for patients with IMID.

KW - Autoimmune Diseases

KW - Covid-19

KW - Tumor Necrosis Factor Inhibitors

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85148675477&partnerID=8YFLogxK

U2 - https://doi.org/10.1136/ard-2022-223464

DO - https://doi.org/10.1136/ard-2022-223464

M3 - Review article

C2 - 36720583

SN - 0003-4967

VL - 82

SP - 883

EP - 885

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 6

M1 - ard-2022-223464

ER -

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Abstract

Keywords

Access to Document

Other files and links

Cite this